Emerge Energy Services LP (NYSE:EMES) announced that the board of directors of its general partner has declared a cash distribution of $0.67 for the second quarter of 2015. This distribution represents a 33% decrease compared to the first quarter 2015 distribution of $1.00 per unit and a 43% decrease compared to the second quarter 2014 distribution of $1.17 per unit. The distribution will be paid on August 13, 2015 to all unitholders of record as of August 5, 2015.Emerge Energy Services LP (NYSE:EMES) belongs to Basic Materials sector. Its net profit margin is 7.70% and weekly performance is -8.50%. On last trading day company shares ended up $18.73. Emerge Energy Services LP (NYSE:EMES) distance from 50-day simple moving average (SMA50) is -39.45%.
Hemispherx Biopharma, Inc. (NYSE MKT: HEB) reported that it has executed an agreement with Emerge Health Pty Ltd. to seek approval of Alferon N Injection® in Australia and New Zealand and to commence distribution of Alferon in both countries on a named-patient basis, where deemed appropriate. Hemispherx Biopharma, Inc. (NYSEMKT:HEB) shares remains unchanged in last trading session and ended the day at $0.19. HEB return on assets is -55.00%. Hemispherx Biopharma, Inc. (NYSEMKT:HEB) quarterly performance is -31.44%.
INC Research Holdings (NASDAQ: INCR) announced the pricing of its secondary offering of 8,000,000 shares of its Class A common stock by certain of its existing stockholders, including affiliates of Avista Capital Partners, L.P.; affiliates of Teachers’ Private Capital, the private investment arm of Ontario Teachers’ Pension Plan Board; and current and former employees of INC Research. INC Research will not receive any proceeds from the sale of the shares by the selling stockholders in this offering. On 11 August, INC Research Holdings, Inc. (NASDAQ:INCR) shares fell -2.25% and was closed at $48.20. INC Research Holdings, Inc. (NASDAQ:INCR) year to date (YTD) performance is 87.62%.
Sterne Agee CRT restated their buy rating on shares of Genuine Parts Company (NYSE:GPC) in a report issued on Wednesday, Marketbeat.com reports. They currently have a $107.00 target price on the stock, down from their previous target price of $108.00. Genuine Parts Company (NYSE:GPC) ended the last trading day at $87.99. Company weekly volatility is calculated as 1.08% and price to cash ratio as 59.60. Genuine Parts Company (NYSE:GPC) showed a weekly performance of -0.52%.
On 3 August, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and privately-held Immuneering Corporation announced that the companies have entered into an agreement in which Teva will purchase a 51% equity share of the genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success. Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares fell -0.29% in last trading session and ended the day at $69.60. TEVA Gross Margin is 56.70% and its return on assets is 5.40%. Teva Pharmaceutical Industries Limited (NYSE:TEVA) quarterly performance is 15.13%.